Claims for Patent: 4,740,463

Summary for Patent: 4,740,463

Title:	Methods and artificial genes for antagonizing the function of an oncogene
Abstract:	A method of antagonizing the effects of an oncogene by constructing an artificial gene which antagonizes the function of the oncogene is described herein. In one embodiment, the artificial gene comprises a transcriptional promoter segment, an inverted oncogene segment, and a polyadenylation segment.
Inventor(s):	Weinberg; Robert A. (Brookline, MA), Bargmann; Cornelia I. (Athens, GA), Stern; David F. (Cambridge, MA)
Assignee:	Massachusetts Institute of Technology (Boston, MA)
Application Number:	06/599,936
Patent Claims:	1. An artificially-contructed gene which, upon introduction into a cell containing an oncogene, antagonizes the function of said oncogene, said artificially-contructed gene containing the following DNA segments: a. a transcriptional promoter segment; b. a polyadenylation segment; and c. a segment of said oncogene, said oncongene segment located between said transcriptional promoter segment and said polyadenylation segment and being inverted with respect to said transcriptional promoter segment and said polyadenylation segment, the polarity of said inverted oncogene segment being the same as that of said transcriptional promoter segment and said polyadenylation segment, whereby transcription of the gene occurs in a direction opposite to the direction of transcription for the oncogene to thereby antagonize the function of said oncogene. 2. An artificially-constructed gene of claim 1 wherein said transcriptional promoter comprises a constitutive promoter segment. 3. An artificially-constructed gene of claim 1 wherein said transcriptional promoter comprises a regulatable promoter segment. 4. An artificially-constructed gene of claim 1 wherein said oncogene segment is derived from an isolated, naturally arising oncogene. 5. An artificially-constructed gene of claim 1 wherein said oncogene segment is derived from the protein-encoding portion of an oncogene. 6. An artificially-constructed gene of claim 1 wherein said oncogene segment is derived from a portion of an oncogene that does not encode protein structure. 7. An artificially-constructed gene of claim 1 wherein said oncogene segment is derived from portions of an oncogene that include protein-encoding portions and portions that encode other than proteins. 8. An artificially-constructed gene of claim 1 wherein said transcriptional promoter segment comprises a viral transcriptional promoter segment. 9. A method of antagonizing the effects of an oncogene in a cell, comprising: a. constructing a gene which, upon transcription in said cell, produces RNA transcript complementary to RNA transcript produced by said oncogene; and b. introducing said gene into the cell containing said oncogene. 10. A method of claim 9 wherein said gene contains a transcriptional promoter segment, a polyadenylation segment and an oncogene segment located between said transcriptional promoter segment and said polyadenylation segment and inverted with respect to said transcriptional promoter segment and said polyadenylation segment, the polarity of said inverted oncogene segment being the same as that of said transcriptional promoter segment and said polyadenylation segment. 11. A method of claim 10 wherein said gene is introduced into said cell by transfection. 12. A method of claim 10 wherein said gene is introduced into said cell by a transducing viral vector. 13. A method of claim 12 wherein said viral vector comprises a retrovirus. 14. A method of claim 10 wherein said gene is introduced into said cell by microinjection. 15. A method of antagonizing the effect of an oncogene in a cell and restoring proto-oncogene function to said cell, comprising: a. constructing a first artificial gene which, upon transcription within said cell, produces an RNA transcript which antagonizes an unspliced RNA transcript involved in the function of said oncogene; b. constructing a second artificial gene which, upon transfection into said cell, produces a spliced RNA transcript which restores proto-oncogene function to said cell and whose function is not antagonized by said RNA transcript produced upon transcription of said first artificial gene in said cell; and c. introducing both of said first and said second artificial genes and into said cell whereby the effect of the oncogene is antagonized and the function of said proto-oncogene is restored. 16. A method of claim 15 wherein said first artificial gene contains intron sequences which reside normally in the unspliced version of the oncogene. 17. A method of claim 16 wherein said second artificial gene is constructed from cDNA produced from an RNA transcript from said proto-oncogene. 18. A method of antagonizing the effect of an oncogene in a cell and restoring proto-oncogene function to said cell, comprising: a. constructing a first artificial gene which, upon transcription in said cell, produces a first RNA transcript complementary to an untranslated portion of messenger RNA of said oncogene; and b. constructing a second artificial gene which, upon transcription in said cell, produces a second RNA transcript lacking untranslated portions which are complementary to sequences present in the first artificial gene, said second RNA transcript being sufficient to restore proto-oncogene function to said cell; and c. introducing said first and said second artificial genes into the cell containing said oncogene. 19. A method of claim 18 wherein said untranslated portions of the messenger RNA of the oncogene comprises sequences of the oncogene messenger RNA transcript lying between the 5' end of the RNA and the site on the RNA at which translation of the encoded oncogene protein is begun. 20. A method of claim 18 wherein said untranslated portions of the messenger RNA comprise sequences of the oncogene messenger RNA lying between the 3' end of the protein-encoding portion of the messenger RNA and the 3' site of the messenger RNA at which site polyadenylation is initiated. 21. A method of claim 18 wherein the untranslated portions of the messenger RNA are a combination of: (a) sequences of the oncogene messenger RNA transcript lying between the 5' end of the RNA and the site on the RNA at which translation of the encoded oncogene protein is begun and (b) sequences of the oncogene messenger RNA lying between the 3' end of the protein-encoding portion of the messenger RNA and the 3' site of the messenger RNA at which site polyadenylation is initiated. 22. A method of antagonizing the function of a gene in a cell, comprising: a. constructing an artificial gene which, upon transcription in said cell, produces RNA transcript complementary to RNA transcript produced by said gene; and b. introducing said artificially constructed gene into the cell containing said gene. 23. An artificially-constructed gene which, upon introduction into a cell containing an oncogene in conjuction with a gene which antagonizes the function of said oncogene, restores proto-oncogene function to said cell, comprising DNA which, upon transcription in said cell, results in production of spliced RNA. 24. An artificially-constructed gene of claim 24 in which the spliced RNA lacks intron DNA sequences. 25. A constructed gene which, upon introduction into a cell containing k-ras oncogene, antagonizes the function of said oncogene, said constructed gene containing the following DNA segments: a. a derivative of the pZIP clone of the Moloney murine leukemia provirus, said derivative being approximately 1 kb in size and comprising: (1) approximately 0.6 kb of the left LTR of Moloney murine leukemia provirus and (2) an additional segment which is the next region of the Moloney murine leukemia virus provirus, the region being approximately 0.4 kb in size and terminating at the first Pst I site normally present in the Moloney leukemia virus genome, the Pst I site being replaced by a BamHI endonuclease site, the derivative containing the transcriptional promoter of the virus; b. a derivative of the pZIP clone of the Moloney murine leukemia provirus, said derivative encompassing a splice-acceptor site of the provirus and originating from the provirus region defined by map units 5.9 to 6.3 and by the endonuclease sites BglIII and XbaI, the BglIII site having been modified to a BamHI endonuclease site and the XbaI site having been modified to an XhoI site; c. a 1.4 kb segment from the tn5 neomycin resistance gene of pBRneo, the segment having been inserted between HindIII and BamHI endonuclease sites at positions 29 and 375, respectively, within plasmid pBR322 and the two endonuclease sites having been replaced, respectively, by an XhoI endonuclease site and a null cleavage site; d. a 0.23 kb Simian virus 40 segment which includes the viral origin of replication and includes nucleotides 160 to 5154, inclusive, of the Simian virus 40 genome, the RII endonuclease site normally present at nucleotide 160 having been replaced by a null cleavage site and the HindIII endonuclease site normally present at nucleotide 5154 having been replaced by an EcoRI cleavage site; e. a 0.58 kb segment of plasmid pBR322 which contains the plasmid origin of replication and originates from a ThaI endonuclease-generated fragment which extends from nucleotide 2521 to nucleotide 3102, inclusive, of the pBR322 plasmid, the left ThaI endonuclease site having been replaced by an EcoRI endonuclease site and the right ThaI endonuclease site having been replaced by an XhoI endonuclease site; f. a 1.05 kb segment from the pZIP clone of the Moloney murine leukemia provirus, the segment of originating at a site 7.75 map units within the provirus and defined by HpaI endonuclease site present in the Moloney murine leukemia virus and including a segement approximately 0.45 kb in size, in which the right LTR of Moloney murine leukemia virus occurs, and an additional segment of the provirus, approximately 0.6 kb in size which extends beyond the right LTR, the HpaI endonuclease site having been replaced by an XhoI endonuclease site; and g. 1.2 kb DNA segment which is homologous to the human cKi-ras 2 gene, the 1.2 kb DNA segment present in the constructed gene at its BamHI endonuclease site and under the control of the transcriptional promoter of (a) such that the 1.2 kb DNA segment serves as template for synthesis of anti-sense RNA.

Details for Patent 4,740,463

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2039-02-26